Evidence map›Paper›PMID 33059741›Full record

ArticleTrials2020

Implementing a nurse-enabled, integrated, shared-care model involving specialists and general practitioners in breast cancer post-treatment follow-up: a study protocol for a phase II randomised controlled trial (the EMINENT trial).

Raymond Javan Chan, Jon Emery, Katharine Cuff, Laisa Teleni, Camilla Simonsen, Jane Turner, Monika Janda, Daniel Mckavanagh, Lee Jones, Emma McKinnell and 10 more

Abstract readClinical Trial Protocol
In one paragraph

Article in Trials, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Cancer survivor preferences for breast cancer follow-up care: a discrete choice experiment.Journal of cancer survivorship : research and practice · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Improved models of care for cancer survivors.Lancet (London, England) · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Raymond Javan ChanDivision of Cancer Services, Proncess Alexandra Hospital, Metro South Health, Brisbane, Queensland, Australia. raymond.chan@qut.edu.au.ORCID http://orcid.org/0000-0003-0248-7046
Jon EmeryDepartment of General Practice and Centre for Cancer Research, University of Melbourne, Melbourne, Victoria, Australia.
Katharine CuffDivision of Cancer Services, Proncess Alexandra Hospital, Metro South Health, Brisbane, Queensland, Australia.
Laisa TeleniSchool of Nursing, Queensland University of Technology, Brisbane, Queensland, Australia.
Camilla SimonsenDivision of Cancer Services, Proncess Alexandra Hospital, Metro South Health, Brisbane, Queensland, Australia.
Jane TurnerFaculty of Medicine, University of Queensland & Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
Monika JandaCentre for Health Services Research, Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia.
Daniel MckavanaghDivision of Cancer Services, Proncess Alexandra Hospital, Metro South Health, Brisbane, Queensland, Australia.
Lee JonesInstitute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Queensland, Australia.
Emma McKinnellDivision of Cancer Services, Proncess Alexandra Hospital, Metro South Health, Brisbane, Queensland, Australia.
Melissa GosperMcGrath Foundation & Princess Alexandra Hospital, Metro South Health, Brisbane, Queensland, Australia.
Juanita RyanDivision of Surgery, Princess Alexandra Hospital, Metro South Health, Brisbane, Queensland, Australia.
Ria JosephSchool of Nursing, Queensland University of Technology, Brisbane, Queensland, Australia.
Bethany CroweDivision of Cancer Services, Proncess Alexandra Hospital, Metro South Health, Brisbane, Queensland, Australia.
Jennifer HarveyRadiation Oncology Centre, Princess Alexandra Hospital, Metro South Health and University of Queensland, Brisbane, Queensland, Australia.
Marissa RyanPharmacy Department, Princess Alexandra Hospital, Metro South Health, Brisbane, Queensland, Australia.
Christine CarringtonPharmacy Department, Princess Alexandra Hospital, Metro South Health, Brisbane, Queensland, Australia.
Rebecca NundSchool of Health and Rehabilitation Sciences, University of Queensland, Brisbane, Queensland, Australia.
Megan CrichtonSchool of Nursing, Queensland University of Technology, Brisbane, Queensland, Australia.
Steven McPhailAustralian Centre For Health Services Innovation (AusHSI), Queensland University of Technology, Brisbane, Queensland, Australia.

Funding

Metro South Study, Education and Research Trust Account (SERTA). Not applicable
6 · The paper itself

Abstract

backgroundDue to advances in early detection and cancer treatment, 5-year relative survival rates for early breast cancer surpass 90% in developed nations. There is increasing focus on promotion of wellness in survivorship and active approaches to reducing morbidity related to treatment; however, current models of follow-up care are heavily reliant on hospital-based specialist-led care. This study aims to test the feasibility of the EMINENT intervention for implementing an integrated, shared-care model involving both cancer centre specialists and community-based general practitioners for early breast cancer post-treatment follow-up.

methodsWe describe a protocol for a phase II, randomised controlled trial with two parallel arms and 1:1 allocation. A total of 60 patients with early-stage breast cancer will be randomised to usual, specialist-led, follow-up care (as determined by the treating surgeons, medical oncologists, and radiation oncologists) or shared follow-up care intervention (i.e. EMINENT). EMINENT is a nurse-enabled, pre-specified shared-care pathway with follow-up responsibilities divided between cancer centre specialists (i.e. surgeons and oncologists) and general practitioners. The primary outcome is health-related quality of life as measured by the Functional Assessment of Cancer Therapy-Breast Cancer. Secondary outcomes include patient experience, acceptance, and satisfaction of care; dietary, physical activity, and sedentary behaviours; financial toxicity; adherence; health resource utilisation; and adverse events. DISCUSSION: The trial is designed to identify the barriers to implementing a shared-care model for breast cancer survivors following treatment. Results of this study will inform a definitive trial testing the effects of shared-care model on health-related quality of life of breast cancer survivors, as well as its ability to alleviate the growing demands on the healthcare system.

trial registrationAustralia and New Zealand Clinical Trials Registry ACTRN12619001594112 . Registered on 19 November 2019.

Indexed as

Breast NeoplasmsGeneral PractitionersAustraliaClinical Trials, Phase II as TopicFemaleHumansNew ZealandQuality of LifeRandomized Controlled Trials as TopicSpecializationEarly breast cancerOncologyProtocolQuality of lifeRandomised controlled trialShared-care

Identifiers

PMID33059741
PMCPMC7558254

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.